Kolexia
Mourlanette Pierre Pneumologie
Mourlanette Pierre
Pneumologie
Clinique Médipôle Garonne Garonne
Toulouse, France
39 Activités
88 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinome pulmonaire non à petites cellules Éosinophilie Adénocarcinome bronchioloalvéolaire Carcinomes Syndrome de Churg-Strauss Spasme coronaire Granulomatose avec polyangéite

Collaborateurs

Voir plus
Debove Pascal
Debove Pascal
Clinique Médipôle Garonne Garonne, Toulouse, France
Carpiuc Ioana
Carpiuc Ioana
Scp Drs Franck Dudouet Et Autres, Oncorad Garonne, Cornebarrieu, France
Ferry Guillaume
Ferry Guillaume
Clinique Médipôle Garonne Garonne, Toulouse, France
Heurtaux William
Heurtaux William
Clinique Médipôle Garonne Garonne, Toulouse, France

Industries

Voir plus
AstraZeneca
19 collaboration(s)
Dernière en 2023
Menarini
9 collaboration(s)
Dernière en 2023
MSD
6 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
3 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Clinical picture, outcomes and predictors of relapse in eosinophilia-associated coronary vasospasm: data from a European multicentric study.
The journal of allergy and clinical immunology. In practice   31 janvier 2024
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   18 janvier 2019
Étude de phase II randomisée non comparative de l’anti-PD-L1 atézolizumab versus chimiothérapie comme traitement de deuxième ligne chez les patients atteints d’un cancer du poumon à petites cellules (CBPC) : résultats de l’essai IFCT-1603
23e Congrès de Pneumologie de Langue Française   01 janvier 2019
A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany   01 octobre 2018
OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)
IASLC 18th World Conference on Lung Cancer   01 novembre 2017
IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients (pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
CPC: Randomized Phase II-III Study of Bevacizumab 7,5 mg/kg in Combination With Chemotherapy Versus Chemotherapy in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy : PCDE (cisPlatin - Cyclophosphamide - epiDoxorubicin - Etoposide) or PE (cisPlatin - Etoposide)
Essai Clinique (Intergroupe Francophone de Cancérologie Thoracique)   09 mars 2016
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Annals of oncology : official journal of the European Society for Medical Oncology   16 février 2015
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.
2014 ASCO Annual Meeting I   20 mai 2014
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   17 janvier 2013